Protalix FY 2024: Record product revenue $53M (+31%), net income $2.9M; debt-free

Protalix BioTherapeutics, Inc.

Revenue from goods $53.0M (+31% YoY), driven by Chiesi sales (+$11.8M); total revenue $53.4M vs $65.5M in 2023.
Net income $2.9M ($0.04/sh diluted) vs $8.3M ($0.12/sh basic) in 2023; lower due to absence of $20M milestone.
Cash $34.8M; convertible notes fully repaid Sep 2024; no warrants remaining after March 2025 expiration.
PRX-115 (gout) phase I completed; phase II expected H2 2025; EMA validated less frequent dosing for pegunigalsidase alfa.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.